GLENMARK — Glenmark Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹289.64bn
- IN₹332.05bn
- IN₹115.83bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.48 | ||
| PEG Ratio (f) | 0.69 | ||
| EPS Growth (f) | 55.27% | ||
| Dividend Yield (f) | 0.28% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.11 | ||
| Price to Tang. Book | 4.2 | ||
| Price to Free Cashflow | 939.53 | ||
| Price to Sales | 2.46 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.96% | ||
| Return on Equity | -13.03% | ||
| Operating Margin | -6.22% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 98,654.68 | 106,409.69 | 109,439.29 | 123,049.03 | 115,832.35 | 124,798.66 | 141,856.72 | 4.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +3.84 | -6.47 | +24.56 | +19.97 | -70.88 | +132.37 | +55.27 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
Directors
- Glenn Saldanha CHM (50)
- V. S. Mani CFO
- Harish Kuber CCO
- Cherylann Pinto EDR
- Blanche Saldanha NED
- Dipankar Bhattacharjee NID (58)
- Rajesh Desai NID (57)
- Sridhar Gorthi NID (49)
- Devendra Mehta NID (84)
- Bernard Munos NID
- Sona Ramasastry NID
- Brian Tempest NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 18th, 1977
- Public Since
- December 10th, 1999
- No. of Shareholders
- 285,461
- No. of Employees
- 15,556
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 282,188,156
- Address
- B D S Marg, MUMBAI, 400099
- Web
- https://glenmarkpharma.com/
- Phone
- +91 2240189999
- Contact
- Harish Kuber
- Auditors
- SURESH SURANA & ASSOCIATES LLP
Upcoming Events for GLENMARK
Q1 2025 Glenmark Pharmaceuticals Ltd Earnings Release
Glenmark Pharmaceuticals Ltd Annual Shareholders Meeting
Similar to GLENMARK
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Glenmark Pharmaceuticals share price?
As of Today at 19:09 UTC, shares in Glenmark Pharmaceuticals are trading at IN₹1,026.40. This share price information is delayed by 15 minutes.
How has the Glenmark Pharmaceuticals share price performed this year?
Shares in Glenmark Pharmaceuticals last closed at IN₹1,026.40 and the price had moved by +100.41% over the past 365 days. In terms of relative price strength the Glenmark Pharmaceuticals share price has outperformed the S&P BSE 100 Index by +55.44% over the past year.
What are the analyst and broker recommendations for Glenmark Pharmaceuticals?
The overall consensus recommendation for Glenmark Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Glenmark Pharmaceuticals dividend yield?
The Glenmark Pharmaceuticals dividend yield is 0.24% based on the trailing twelve month period.
Does Glenmark Pharmaceuticals pay a dividend?
Last year, Glenmark Pharmaceuticals paid a total dividend of IN₹2.50, and it currently has a trailing dividend yield of 0.24%. We do not have any data on when Glenmark Pharmaceuticals is to next pay dividends.
When does Glenmark Pharmaceuticals next pay dividends?
We do not have data on when Glenmark Pharmaceuticals is to next pay dividends. The historic dividend yield on Glenmark Pharmaceuticals shares is currently 0.24%.
How do I buy Glenmark Pharmaceuticals shares?
To buy shares in Glenmark Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Glenmark Pharmaceuticals?
As of the previous close price of IN₹1,026.40, shares in Glenmark Pharmaceuticals had a market capitalisation of IN₹289.64bn.
Where are Glenmark Pharmaceuticals shares listed?
Here are the trading details for Glenmark Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: GLENMARK
What kind of share is Glenmark Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Glenmark Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Glenmark Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Glenmark Pharmaceuticals is IN₹871.71. That is 15.07% below the last closing price of IN₹1,026.40.
Analysts covering Glenmark Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of IN₹27.01 for the next financial year.
What is the trend in the Glenmark Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glenmark Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +12.28%.
As of the last closing price of IN₹1,026.40, shares in Glenmark Pharmaceuticals were trading +23.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Glenmark Pharmaceuticals PE Ratio?
The Glenmark Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 24.48. The shares last closed at IN₹1,026.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals' management team is headed by:
- Glenn Saldanha - CHM
- V. S. Mani - CFO
- Harish Kuber - CCO
- Cherylann Pinto - EDR
- Blanche Saldanha - NED
- Dipankar Bhattacharjee - NID
- Rajesh Desai - NID
- Sridhar Gorthi - NID
- Devendra Mehta - NID
- Bernard Munos - NID
- Sona Ramasastry - NID
- Brian Tempest - NID